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Abstract
Background: Mycobacterium avium complex (MAC) lung diseases generally cause chronic disease in immunocompetent
hosts. Although a few studies have examined health-related quality of life (HRQL) in patients with MAC lung disease,
there have been no large studies. This study aimed to evaluate HRQL and its correlation with clinical outcomes in MAC
lung disease.
Methods: A cross-sectional study was conducted at Keio University Hospital to investigate the factors associated with
HRQL in pulmonary nontuberculous mycobacterial diseases. MAC lung diseases were diagnosed according to the 2007
ATS/IDSA guidelines for nontuberculous mycobacterial diseases. The 36-item short form health survey (SF-36) was
administered to assess clinical outcomes. Clinical variables included treatment status, latest haematological data, and
bacterial smear and culture results.
Results: The SF-36 scores for the 235 patients (median age, 69 years; 45 men and 190 women) with MAC lung disease,
except for the bodily pain and mental health subscale scores, were significantly lower than the Japanese population
norms. In the multivariable analyses, current treatment for MAC and a positive sputum smear or culture within the past
year were significantly associated with lower SF-36 scores. C-reactive protein (CRP) and age showed stronger inverse
correlations with SF-36 scores.
Conclusions: HRQL, especially the physical component, was impaired in patients with MAC lung diseases; this appears
to be related with current treatment status, positive sputum smear or culture within the previous year, and particularly
CRP and age. Further studies including qualitative assessments are needed to investigate the efficacy of CRP as a
marker for progression or treatment response in MAC lung disease.
Trial registration: Clinical trial registered with UMIN (UMIN000007964).
Keywords: C-reactive protein, Mycobacterium avium complex, Nontuberculous mycobacteria, Quality of life
* Correspondence: ishii@z6.keio.jp
1Division of Pulmonary Medicine, Department of Medicine, Keio University
School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
Full list of author information is available at the end of the article
© 2015 Asakura et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Asakura et al. Respiratory Research  (2015) 16:145 
DOI 10.1186/s12931-015-0304-5
Background
The incidence of nontuberculous mycobacterial lung
disease is increasing worldwide [1, 2]. Mycobacterium
avium complex (MAC) lung disease, the most common
nontuberculous mycobacterial disease, generally causes
chronic, slowly progressive disease in immunocompetent
hosts [3].
Therapy involving multiple antimicrobials against MAC
is generally effective because it decreases the bacterial
load, resulting in a change from a positive to negative
sputum culture. However, established MAC lung diseases
are often incurable or recurrent, resembling other chronic
diseases such as diabetes mellitus (DM), chronic obstruct-
ive pulmonary disease (COPD), or interstitial lung disease
(ILD). Long-term treatment with multiple antimicrobial
agents and their side effects frequently contribute to
patient burden.
As an indicator of overall health status, patient-reported
outcome measures representing health-related quality of
life (HRQL), or the individual’s satisfaction or happiness
with aspects of life related to health, have become import-
ant in the current treatment guidelines for MAC lung
disease, in addition to conventional measures of infection
control or cure rate [3, 4]. Furthermore, HRQL provides
information for health management and policy decisions
[5]. The 36-item Short-Form health survey (SF-36) version
2 is a general HRQL measure and has been used in
different chronic respiratory diseases, including ILD [6],
sarcoidosis [7], bronchiectasis [8], pulmonary tuberculosis
[9], and COPD [10]. With MAC lung disease, only two
studies reported impaired HRQL, as assessed using the
SF-36 and St. George’s Respiratory Questionnaire (SGRQ)
[11, 12], a respiratory disease-specific HRQL instrument
originally designed for patients with COPD [13]. However,
the correlations between HRQL and variables such as
treatment status, sputum culture and smear results, and
haematological data remain unknown.
This study aimed to evaluate HRQL, as assessed using
the SF-36, and identify its clinical determinants in a
large population of consecutive patients with MAC lung
disease.
Methods
Study population
A cross-sectional study was conducted at Keio University
Hospital with patients with pulmonary nontuberculous
mycobacterial diseases (University Hospital Medical Infor-
mation Network: UMIN000007964). The study protocol
was approved by the Keio University Hospital ethics
review board. Written informed consent was obtained
from each patient.
We enrolled 285 patients aged ≥20 years who were
diagnosed with nontuberculous mycobacterial diseases
between May 2012 and February 2014 according to the
2007 American Thoracic Society/Infectious Disease Soci-
ety of America guidelines for the diagnosis of nontubercu-
lous mycobacterial diseases [3]. We excluded 31 patients
who could not complete the HRQL questionnaire and 19
patients with nontuberculous mycobacterial diseases other
than MAC. The final sample included 235 patients with
MAC lung disease.
Health-related quality of life assessment
All patients completed the SF-36 version 2 [14] and SGRQ
in Japanese [13, 15, 16]. The SF-36 consists eight sub-
scales: physical functioning, role-physical, bodily pain,
general health, vitality, social functioning, role-emotional,
and mental health. These eight subscales provide three
summary scores, which were adjusted for Japanese pa-
tients: physical, mental, and role/social component sum-
mary scores [17]. All scores were transformed to fit a
norm-based score for the general Japanese population,
with a mean score of 50 and standard deviation of
10. Lower scores indicate poorer HRQL. The internal
consistency of the SF-36 was assessed using Cronbach’s α.
SGRQ scores (range, 0–100) were calculated for the
total questionnaire as well as for each of the three
components; the symptoms, activity, and impact compo-
nents measure respiratory symptoms, impairment of phys-
ical activity, and social and psychological disturbances,
respectively.
Assessment of clinical parameters
Demographic data included age at diagnosis, disease dur-
ation, body mass index (BMI), smoking status, underlying
pulmonary diseases, comorbidities using the age-adjusted
Charlson comorbidity index (CCI) [18], treatment status,
and bacterial smear and culture results for M. avium and
M. intracellulare at study enrolment. Haematological
investigations and pulmonary function tests were per-
formed after study enrolment. Treatment status was
classified as never treated, previously treated, or currently
treated. The lower respiratory tract specimens were cul-
tured on egg-based solid media (Kyokuto Pharmaceutical
Industrial Co., Ltd., Tokyo, Japan) or mycobacteria growth
indicator tubes (Becton, Dickinson and Co., Sparks, MD,
USA). The AccuProbe system (Gen-Probe Inc., San Diego,
CA, USA) was used to identify MAC isolates. The COBAS
AMPLICOR system (Roche Diagnostic Co., Ltd., Tokyo,
Japan) and DNA–DNA hybridization test (Kyokuto
Pharmaceutical Industrial Co., Ltd.) were used to classify
MAC isolates as M. avium or M. intracellulare; unspeci-
fied MAC isolates were categorized as MAC. Sputum
smears or cultures were defined as negative based on
results obtained in the previous year. If patients did not
cough up sputum, they were recorded as negative [19].
Pulmonary function tests were performed with patients
with a stable condition using an electronic spirometer
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according to the American Thoracic Society guidelines
[20].
Statistical analyses
Correlations between two continuous variables were ana-
lysed using Spearman’s correlation coefficients. Compari-
sons were conducted using Student’s t-tests between two
groups and Tukey's tests among three groups. Analyses of
covariance (ANCOVA), adjusted for age, sex, CCI, smok-
ing status, BMI, and underlying pulmonary disease, were
used to analyse group differences. To identify the relative
contributions of factors to SF-36 scores lower than the
Japanese population norms, factors significantly associated
with lower norm-based SF-36 scores in the univariate
analyses were entered into a stepwise forward and back-
ward multiple regression model for multivariate analysis.
All P values were two-tailed; P < 0.05 was considered
significant. Statistical analyses were conducted using JMP
v11.0 (SAS Institute Japan Ltd, Tokyo, Japan).
Results
Patient characteristics and clinical features
The median (interquartile range) age of the patients was
69 (64–76) years; 190 (80.9 %) patients were women,
and 215 (91.4 %) patients had never smoked (Table 1).
Mean BMI was 19.5 (17.5–21.2) kg/m2. M. intracellulare
(5.1 %) was the least commonly isolated bacteria. Under-
lying pulmonary diseases were present in 36 (15.3 %)
patients. Regarding treatment status, 110 (46.8 %)
patients were never treated, 80 (34.0 %) were previously
treated, and 45 (19.1 %) were currently treated. Smear
tests or sputum cultures were positive for MAC in 78
(33.2 %) and 132 (56.5 %) patients, respectively. The
pulmonary function test results were within the nor-
mal range; percent-predicted functional volume capacity
(%FVC), percent-predicted forced expiratory volume in
1 s, and percent-predicted diffusing capacity of the lung
for carbon monoxide (%DLCO) were 95.7 (interquartile
range, 80.1–108.0), 87.3 (interquartile range, 72.7–99.1),
and 88.7 (interquartile range, 78.2–104.6), respectively.
Norm-based SF-36 scores
The norm-based SF-36 scores are shown in Fig. 1. Of
the subscale components, the bodily pain, and mental
health scores were within the range of the Japanese
population norms; however, the physical functioning,
role-physical, general health, vitality, social functioning,
and role-emotional subscale scores were significantly
lower than the Japanese population norms. The general
health subscale represented the largest difference (differ-
ence, 6.4; 95 % CI, 5.1–7.7). For the summary scores, the
physical and role/social component summary scores were
significantly lower than the Japanese population norms.
The physical component summary score represented the
largest difference (difference, 4.8; 95 % CI, 3.3–6.3).
Correlations between SF-36 subscale or component
summary scores and clinical parameters, physiological
parameters, and SGRQ scores
The internal consistency of the SF-36 was good (Cronbach’s
α, 0.90–0.92). The correlations between the SF-36 subscale
or component summary scores and pulmonary func-
tion tests and SGRQ scores are shown in Table 2. All
SF-36 subscale scores were significantly correlated
Table 1 Clinical characteristics of patients with Mycobacterium
avium comlex lung disease (n = 235)
Median (interquartile range)
or number (%)
Age, years 69 (64–76)
Disease duration, years 5 (3–10)
Sex, female 190 (80.8)
Body mass index, kg/m2 19.5 (17.5–21.2)
Mycobacterium species
Mycobacterium avium 128 (54.5)
Mycobacterium intracellulare 12 (5.1)
MAC 95 (40.4)
Smoking status
Never 215 (91.5)
Former 20 (8.5)
Current 0 (0)
Charlson comorbidity index 3 (3–4)
Underlying pulmonary diseases
Asthma 8 (3.4)
COPD 2 (0.9)
Interstitial lung disease 1 (0.4)
Lung cancer 2 (0.9)
Old pulmonary TB 23 (9.8)
Treatment status
Never treated 110 (46.8)
Previously treated 45 (19.1)
Currently treated 80 (34.0)
Bacterial status in the previous year
Positive smear 78 (33.2)
Positive culture 132 (56.1)
%FVC, % 95.7 (80.1–108.0)
%FEV1, % 87.3 (72.7–99.1)
%DLCO, % 88.7 (78.2–104.6)
MAC Mycobacterium avium complex, COPD chronic obstructive pulmonary
disease, TB tuberculosis, FVC functional volume capacity, FEV1 forced
expiratory volume in 1 s, DLCO diffusing capacity of the lung for
carbon monoxide
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with each other and with the component summary
scores. All SF-36 subscale or component summary
scores had significant and moderate to strong correla-
tions with all SGRQ scores.
Pulmonary function showed stronger correlations with
the physical functioning, role-physical, and general health
subscale scores and the physical component summary
score than the other subscale scores or component sum-
mary scores. Age was significantly correlated with all SF-
36 scores except the general health, vitality, and mental
health subscale scores and the mental component sum-
mary score; the disease duration was poorly correlated
with all SF-36 scores. BMI had a significant but weak
correlation with the SF-36 scores, excluding the physical
component summary score. Age-adjusted CCI had a
significant and moderate correlation with the physical
functioning and role-physical subscale scores and the
physical component summary scores.
Fig. 1 Norm-based SF-36 scores in patients with MAC lung disease.
Error bars represent the 95 % confidence intervals. Higher SF-36 scores
are related with better health-related quality of life (HRQL). *Scores <50
indicate poorer HRQL than the Japanese population norms. SF-36:
36-item short form healthy survey; MAC, Mycobacterium avium
complex; PF, physical functioning; RP, role - physical; BP, bodily pain;
GH, general health; VT, vitality; SF, social functioning; RE, role-
emotional; MH, mental health; PCS, physical component summary;
MCS, mental component summary; RCS, role/social component
summary
Table 2 Spearman’s correlations between the SF-36 scores and clinical parameters in patients with MAC lung disease (n = 235)
Age Diseaseduration
BMI, 
kg/m2 CCI %FVC
%FEV1 %DLCO SGRQ-
symptom
SGRQ-
activity
SGRQ-
impact
SGRQ
-total
SF-
36-PF
SF-
36-RP
SF-
36-BP
SF-36-
GH
SF-
36-VT
SF-
36-SF
SF-
36-RE
SF-
36-MH
SF-
36-PCS
SF-
36-MCS
SF-36-
RCS
Age
Disease 
duration -0.02
BMI, kg/m2 0.04 0.07
CCI 0.83§ 0.003 -0.04
%FVC -0.13* -0.05 0.31§ -0.14*
%FEV1 -0.05 -0.17* 0.13* -0.08 0.80
§
%DLCO -0.05 -0.13 -0.004 -0.09 0.40
§ 0.39§
SGRQ-
symptom 0.20
† 0.09 -0.22‡ 0.12 -0.35§ -0.36§ -0.22‡
SGRQ-activity 0.36§ 0.05 -0.15* 0.33§ -0.33§ -0.30§ -0.32§ 0.61§
SGRQ-impact 0.24‡ 0.04 -0.21† 0.20† -0.35§ -0.38§ -0.23‡ 0.76§ 0.74§
SGRQ-total 0.31§ 0.06 -0.20† 0.26§ -0.37§ -0.37§ -0.29§ 0.82§ 0.90§ 0.94§
SF-36-PF -0.49§ -0.02 0.16* -0.44§ 0.39§ 0.32§ 0.30§ -0.50§ -0.76§ -0.62§ -0.71§
SF-36-RP -0.37§ 0.03 0.24‡ -0.38§ 0.28§ 0.20† 0.26§ -0.50§ -0.67§ -0.65§ -0.69§ 0.73§
SF-36-BP -0.21‡ -0.01 0.19† -0.24‡ 0.12 0.06 0.18† -0.34§ -0.42§ -0.38§ -0.42§ 0.48§ 0.56§
SF-36-GH -0.12 -0.02 0.24‡ -0.16* 0.30§ 0.25§ 0.28§ -0.51§ -0.59§ -0.66§ -0.66§ 0.56§ 0.59§ 0.44§
SF-36-VT -0.12 0.08 0.21† -0.12 0.20† 0.14* 0.20† -0.48§ -0.55§ -0.58§ -0.60§ 0.55§ 0.65§ 0.51§ 0.67§
SF-36-SF -0.20† 0.05 0.21† -0.23‡ 0.22† 0.16* 0.15* -0.46§ -0.51§ -0.59§ -0.59§ 0.57§ 0.71§ 0.50§ 0.59§ 0.64§
SF-36-RE -0.24‡ 0.03 0.22‡ -0.23‡ 0.25‡ 0.14* 0.17* -0.44§ -0.52§ -0.52§ -0.56§ 0.55§ 0.78§ 0.47§ 0.51§ 0.60§ 0.66§
SF-36-MH -0.03 0.14* 0.17* -0.08 0.12 0.07 0.08 -0.31§ -0.37§ -0.43§ -0.42§ 0.37§ 0.58§ 0.44§ 0.54§ 0.69§ 0.63§ 0.65§
SF-36-PCS -0.44§ -0.09 0.12 -0.40§ 0.28§ 0.22‡ 0.31§ -0.39§ -0.63§ -0.49§ -0.58§ 0.80§ 0.57§ 0.62§ 0.53§ 0.34§ 0.27§ 0.33§ 0.08
SF-36-MCS 0.13 0.09 0.17† 0.09 0.08 0.05 0.07 -0.32§ -0.27§ -0.40§ -0.37§ 0.18§ 0.30§ 0.43§ 0.67§ 0.76§ 0.49§ 0.31§ 0.74§ 0.06
SF-36-RCS -0.23‡ 0.08 0.19† -0.25‡ 0.18† 0.11 0.10 -0.35§ -0.42§ -0.43§ -0.45§ 0.45§ 0.76§ 0.29§ 0.28§ 0.46§ 0.77§ 0.85§ 0.59§ 0.09 0.16*
*P < 0.05, †P < 0.01, ‡P < 0.001, §P < 0.0001
BMI, body mass index; CCI, Charlson comorbidity index; FVC, functional volume capacity; FEV1, forced expiratory volume in 1 s; DLco, diffusing capacity of the lung for 
carbon monoxide; SGRQ, St. George's Respiratory Questionnaire; PF, physical functioning; RP, role physical; BP, bodily pain; GH, general health; VT, vitality; SF, social 
functioning; RE, role-emotional; MH, mental health; PCS, physical component summary; MCS, mental component summary; RCS, role/social component summary
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Correlations between SF-36 subscale or component
summary scores and haematological data
Correlations between the SF-36 subscale or component
summary scores and haematological data are shown
in Table 3. Haemoglobin (Hb) and C-reactive protein
(CRP) levels were significantly correlated with the physical
functioning, role-physical, general health, vitality, social
functioning, and role-emotional subscale scores and the
physical and role/social component summary scores; CRP
was strongly correlated with the physical functioning sub-
scale score. Alkaline phosphatase, sialylated carbohydrate
antigen KL-6, and white blood cell count were moderately
correlated with physical component summary score. Hb
was moderately correlated with the physical functioning
and role-physical subscale scores and physical component
summary scores.
Comparisons between SF-36 subscale or component
summary scores using ANCOVA
The physical functioning, role-physical, general health,
and social functioning subscale and physical component
summary scores significantly differed between the never-
and currently-treated groups and between the previ-
ously- and currently-treated groups, but not between the
never- and previously-treated groups (Fig. 2a). The phys-
ical functioning, role-physical, general health, vitality,
and role-emotional subscale scores and the physical and
role/social component summary scores significantly dif-
fered by sputum smear or culture results (Fig. 2b, c).
Multivariate determinants for SF-36 subscale or component
summary scores
The stepwise multiple regression analysis included age,
sex, age-adjusted CCI, BMI, smoking status, disease
duration, underlying pulmonary diseases, treatment status
(currently treated vs previously/never treated), positive
sputum smear or culture, pulmonary function, Hb levels,
and CRP levels (Table 4). CRP levels, age, %FVC, under-
lying pulmonary disease, %DLCO, current treatment, and
sputum culture significantly predicted physical function-
ing subscale score, accounting for 56.0 % of the variance.
CRP levels, age, sputum culture, and %DLCO significantly
predicted role-physical subscale scores, accounting for
34.5 % of the variance. %FVC, age, CRP levels, and %DLCO
significantly predicted general health subscale score, ac-
counting for 26.8 % of the variance. %FVC, CRP level, and
sputum culture significantly predicted the vitality subscale
score, accounting for 17.6 % of the variance. CRP level,
age, and %FVC significantly predicted social functioning
and role-emotional subscale scores, accounting for 26.5 %
and 18.7 % of the variance, respectively. Regarding the
physical component summary score, age, CRP levels,
%DLCO, sputum culture, and underlying pulmonary dis-
eases were significant predictors, accounting for 47.4 % of
the variance. CRP levels and age were significant predic-
tors for almost all SF-36 scores that were lower than the
Japanese population norms.
Discussion
Based on this study of HRQL in patients with MAC lung
disease and the correlations between SF-36 and clinical
factors, there were three important findings. First, patients
with MAC lung disease have significantly poorer HRQL
than the Japanese population norms, implying impaired
physical performance and social activities. Second, we
identified two clinically important factors associated with
lower HRQL: currently receiving treatment and positive
sputum smear or culture within the previous year. Finally,
Table 3 Spearman’s correlations between SF-36 scores and haematological data in patients with MAC lung disease (n = 235)
Median (interquartile range) PF RP BP GH VT SF RE MH PCS MCS RCS
TP, g/dL 6.9 (6.7–7.3) −0.11 −0.06 −0.34 −0.13 −0.31 0.06 0.04 −0.02 −0.16 −0.04 0.10
Creatinine, mg/dL 0.66 (0.58–0.76) 0.05 0.10 0.15 0.15 0.17* 0.12 0.08 0.09 0.06 0.18* 0.02
LDH, IU/L 179 (162–199) −0.16 −0.08 −0.05 −0.05 −0.08 −0.09 −0.04 −0.09 −0.09 −0.04 −0.07
ALP, IU/L 230 (187–289) −0.25** −0.21* −0.12 −0.19** −0.12 −0.10 −0.19* −0.11 −0.24** −0.04 −0.11
KL-6, U/mL 251 (194–393) −0.22** −0.26*** −0.09 −0.20* −0.16 −0.12 −0.19* −0.10 −0.19* −0.06 −0.13
WBC, /μL 5600 (4500–6400) −0.17* −0.15 0.00 −0.13 −0.07 −0.01 −0.10 −0.002 −0.21** 0.06 −0.04
Haemoglobin, g/dL 13.0 (12.1–13.7) 0.30*** 0.23** 0.14 0.18* 0.19* 0.24** 0.23** 0.09 0.22** 0.003 0.20*
Platelets, /μL 21.3 (18.0–24.9) −0.005 −0.001 0.07 −0.02 0.01 0.01 0.01 0.02 −0.02 0.02 0.03
CRP, mg/dL 0.06 (0.02–0.33) −0.35*** −0.30*** −0.13 −0.20* −0.18* −0.26*** −0.24** −0.10 −0.28*** 0.02 −0.23**
SPD, ng/mL 78 (54–12) −0.19* −0.22** −0.10 −0.03 −0.06 −0.10 −0.17* −0.06 −0.13 0.03 −0.16
GPL-IgA core, U/mL 1.5 (0.5–7.2) −0.10 −0.13 −0.10 −0.11 −0.19* −0.12 −0.14 −0.13 −0.04 −0.13 −0.10
SF-36 36-item short form healthy survey, MAC Mycobacterium avium complex, PF physical functioning, RP role physical, BP bodily pain, GH general health, VT vitality,
SF social functioning, RE role-emotional, MH mental health, PCS physical component summary, MCS mental component summary, RCS role/social component
summary, TP total protein, LDH lactate dehydrogenase, ALP alkaline phosphatase, KL-6 sialylated carbohydrate antigen KL-6, WBC white blood cell, CRP C-reactive
protein, SPD surfactant protein d, GPL-IgA core glycopeptidolipid core immunoglobulin A antibody
*P < 0.01, **P < 0.001, ***P < 0.0001
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we also identified several factors, including CRP levels and
age that were strongly associated with poorer HRQL.
A number of previous studies have demonstrated im-
paired HRQL in various chronic diseases, including DM;
patients with DM had lower scores for all eight SF-36
subscales compared with US population norms [21] and
a higher risk for low physical component summary scores
compared with older Japanese adults without DM [22]. In
stroke patients, neurological impairments were associated
with functional disability shortly after the stroke; lower
physical and mental component summary scores were
present at 3 months and 1 year after the stroke [23]. In
addition, in the general population, common chronic
conditions (e.g., ischemic heart disease, DM, and arthritis)
notably impacted the physical functioning, general health,
and bodily pain subscales, respectively, in a previous study.
Furthermore, lower SF-36 physical component summary
scores have been reported for patients with arthritis,
chronic lung disease, or congestive heart failure [24]. The
severity of chronic lung diseases, including chronic bron-
chitis, emphysema, and asthma, are reportedly significantly
correlated with all eight SF-36 scales, reflecting respiratory
symptoms [25, 26]; the physical component summary
score is primarily affected in COPD [27], asthma [28], ILD
[6], and sarcoidosis [7], while bronchiectasis impacts both
the physical and mental component summary scores [8].
Fig. 2 Results of the comparisons of SF-36 subscale or component summary scores. Displayed as least square means, based on (a) treatment
status, (b) sputum smear, and (c) sputum culture after adjustment for age, sex, Charlson comorbidity index, smoking status, body mass index, and
underlying pulmonary disease in patients with pulmonary Mycobacterium avium complex lung diseases. Error bars represent the standard error of
the mean. Comparisons were conducted between two groups using Student t-tests and among three groups using Tukey's tests. *P < 0.05,
†P < 0.01, ‡P < 0.001. SF-36: 36-item short form healthy survey; PF, physical functioning; RP, role physical; BP, bodily pain; SF, social
functioning; GH, general health; VT, vitality; RE, role-emotional; MH, mental health; PCS, physical component summary; MCS, mental
component summary; RCS, role/social component summary
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To the best of our knowledge, only two studies have
evaluated HRQL in patients with MAC lung disease.
Impaired SGRQ-assessed HRQL was associated with
high-resolution computed tomography findings [12]. Fur-
thermore, in a study based in Canada, all of the subscale
and component summary scores were impaired [11];
comparatively, the bodily pain and mental health subscale
scores, and the mental component summary scores were
within the population norm ranges in the present study.
Pulmonary function was better, and there were fewer
patients being currently treated in the present study,
which might explain the differences in the results, in
addition to differences in nationality or race.
In the present study, there were differences in HRQL,
as evaluated using SF-36, between the treatment sta-
tuses. Patients currently receiving medical treatment had
lower HRQL than the other treatment groups, while
there were no differences in HRQL between the never-
and previously-treated groups. These results suggest that
multiple antimicrobial therapies against MAC might
have a significant negative impact on HRQL, although
patients who are currently receiving treatment tend to
have more severe MAC lung disease. Sputum status, espe-
cially in culture conversion, has been used classically to
evaluate infection control in MAC lung disease [29–31].
Notably, our data indicate the ability of sputum status to
measure HRQL in patients with MAC lung disease.
To the best of our knowledge, our study is the first to
demonstrate strong correlations between SF-36 scores
and multiple clinical factors including patient character-
istics, sputum culture status, pulmonary function, and
haematological data. Age has already been reported as
an important factor negatively influencing the SF-36
score [32]; given the aging population, this correlation is
likely to become more important [33]. Furthermore, our
study revealed that CRP might reflect HRQL-associated
disease activity in patients with MAC lung disease. CRP
is a biomarker that is elevated in acute and chronic
inflammation such as that in infectious disease or non-
infectious chronic diseases. Previous studies in chronic
disease have demonstrated the ability of CRP to predict
cardiovascular events in patients with arteriosclerotic
diseases [34], treatment failure in tuberculosis [35] or
human immunodeficiency virus infection [36], and dis-
ease progression in ILD with systemic scleroderma [37].
CRP might be a better and more convenient marker
than a physiological parameter and could potentially be
a marker of disease progression or treatment response.
Our study has several potential limitations. First, the
cross-sectional design creates challenges in determining
causal relationships, particularly regarding the influence
of treatment. Second, by including only patients who
could complete the SF-36, SGRQ, and pulmonary func-
tion tests, we might have excluded patients with more
severe disease. However, we believe the present findings
also apply to patients with severe disease because the
pulmonary function and some of the haematological
results were significantly correlated with HRQL.
Conclusions
In conclusion, patients with MAC lung disease have sig-
nificantly lower HRQL than the Japanese population
norms, indicating impaired physical performance and
social activities. These impairments appear to be related
Table 4 Multivariate determinants for SF-36 scores lower than
the Japanese population norms (n = 235)
SF-36 P-value Cumulative R2 (%)
PF CRP <0.0001 26.1
Age <0.0001 38.7
%FVC 0.0002 44.9
UPD 0.0008 49.5
%DLCO 0.0045 52.5
Current treatment 0.0206 54.5
Sputum culture 0.0441 56.0
RP CRP <0.0001 15.3
Age 0.0001 25.3
Sputum culture 0.0007 31.6
%DLCO 0.0110 34.5
GH %FVC <0.0001 13.1
Age 0.0009 20.1
CRP 0.0076 24.4
%DLCO 0.0397 26.8
VT %FVC 0.0006 8.6
CRP 0.0093 13.2
Sputum culture 0.0100 17.6
SF CRP <0.0001 18.8
Age 0.0062 23.3
%FVC 0.0202 26.5
RE CRP 0.0002 9.8
%FVC 0.0068 14.7
Age 0.0122 18.7
PCS Age <0.0001 21.6
CRP <0.0001 34.9
%DLCO 0.0003 41.1
Sputum culture 0.0125 43.9
UPD 0.0290 47.4
RCS CRP 0.0001 10.4
Age 0.0345 13.4
SF-36 36-item short form healthy survey, PF physical functioning, CRP C-reactive
protein, FVC functional volume capacity, UPD underlying pulmonary disease,
DLCO diffusing capacity of the lung for carbon monoxide, RP role physical,
GH general health, SF social functioning, RE role-emotional, PCS physical
component summary, RCS role/social component summary
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with current treatment status and positive sputum smear
or culture within the previous year. CRP levels and age
were the most significant factors for impaired HRQL.
These findings could affect treatment initiation decisions
by physicians. Further studies including qualitative assess-
ments are needed to investigate the efficacy of CRP as a
marker for progression or treatment response in MAC
lung disease.
Abbreviations
%DLCO: percent - predicted diffusing capacity of the lung for carbon
monoxide; %FVC: percent-predicted functional volume capacity;
ANCOVA: analyses of covariance; BMI: body mass index; CCI: Charlson
comorbidity index; CI: confidence interval; COPD: chronic pulmonary
obstructive disease; CRP: C-reactive protein; DM: diabetes mellitus;
Hb: haemoglobin; HRQL: health-related quality of life; ILD: interstitial lung
disease; MAC: Mycobacterium avium complex; SF-36: 36-item short form
healthy survey; SGRQ: St. George’s Respiratory Questionnaire.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
T. Asakura, YF, MI, and NH designed the study, acquired data, interpreted
data, wrote, revised, and approved the final manuscript. HN and KY designed
the study, acquired data, interpreted data, revised, and approved the final
manuscript. SS, T. Asami, TK, HF, YU, TN, ST, and TB acquired data, interpreted
data, revised, and approved the final manuscript.
Acknowledgements
We thank Chiyomi Uemura and Akiko Takahashi for assistance in collecting
the data.
Author details
1Division of Pulmonary Medicine, Department of Medicine, Keio University
School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
2Center for Infectious Diseases and Infection Control, Keio University School
of Medicine, Tokyo, Japan. 3Keio University Health Center, Tokyo, Japan.
Received: 23 September 2015 Accepted: 19 November 2015
References
1. Satta G, McHugh TD, Mountford J, Abubakar I, Lipman M. Managing pulmonary
nontuberculous mycobacterial infection. time for a patient-centered approach.
Ann Am Thorac Soc. 2014;11:117–21. doi:10.1513/AnnalsATS.201308-278OT.
2. Kendall BA, Winthrop KL. Update on the epidemiology of pulmonary
nontuberculous mycobacterial infections. Semin Respir Crit Care Med.
2013;34:87–94. doi:10.1055/s-0033-1333567.
3. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al.
An official ATS/IDSA statement: diagnosis, treatment, and prevention of
nontuberculous mycobacterial diseases. Am J Respir Crit Care Med.
2007;175:367–416. doi:10.1164/rccm.200604-571ST.
4. Management of opportunist mycobacterial infections: Joint Tuberculosis
Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis
Committee of the British Thoracic Society. Thorax. 2000;55:210–8.
5. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life.
Ann Intern Med. 1993;118:622–9.
6. Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health-related quality
of life in patients with interstitial lung disease. Chest. 1999;116:1175–82.
7. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. Health-related
quality of life of persons with sarcoidosis. Chest. 2004;125:997–1004.
8. Guilemany JM, Alobid I, Angrill J, Ballesteros F, Bernal-Sprekelsen M, Picado C,
et al. The impact of bronchiectasis associated to sinonasal disease on quality of
life. Respir Med. 2006;100:1997–2003. doi:10.1016/j.rmed.2006.02.016.
9. Dion MJ, Tousignant P, Bourbeau J, Menzies D, Schwartzman K. Feasibility
and reliability of health-related quality of life measurements among
tuberculosis patients. Qual Life Res. 2004;13:653–65.
10. Miyazaki M, Nakamura H, Chubachi S, Sasaki M, Haraguchi M, Yoshida S,
et al. Analysis of comorbid factors that increase the COPD assessment test
scores. Respir Res. 2014;15:13. doi:10.1186/1465-9921-15-13.
11. Mehta M, Marras TK. Impaired health-related quality of life in pulmonary
nontuberculous mycobacterial disease. Respir Med. 2011;105:1718–25.
doi:10.1016/j.rmed.2011.08.004.
12. Maekawa K, Ito Y, Oga T, Hirai T, Kubo T, Fujita K, et al. High-resolution
computed tomography and health-related quality of life in
Mycobacterium avium complex disease. Int J Tuberc Lung Dis.
2013;17:829–35. doi:10.5588/ijtld.12.0672.
13. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete
measure of health status for chronic airflow limitation. The St. George's
Respiratory Questionnaire. Am Rev Respir Dis. 1992;145:1321–7.
doi:10.1164/ajrccm/145.6.1321.
14. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation,
and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol.
1998;51:1037–44.
15. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Comparison of
discriminative properties among disease-specific questionnaires for
measuring health-related quality of life in patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med. 1998;157:785–90.
doi:10.1164/ajrccm.157.3.9703055.
16. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Analysis of
clinical methods used to evaluate dyspnea in patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158:1185–9.
doi:10.1164/ajrccm.158.4.9802091.
17. Suzukamo Y, Fukuhara S, Green J, Kosinski M, Gandek B, Ware JE. Validation
testing of a three-component model of Short Form-36 scores. J Clin
Epidemiol. 2011;64:301–8. doi:10.1016/j.jclinepi.2010.04.017.
18. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined
comorbidity index. J Clin Epidemiol. 1994;47:1245–51.
19. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of
aminoglycoside infusion with combined therapy for pulmonary
Mycobacterium avium complex disease. Respir Med. 2007;101:130–8.
doi:10.1016/j.rmed.2006.04.002.
20. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am
J Respir Crit Care Med. 1995;152:1107–36. doi:10.1164/ajrccm.152.3.7663792.
21. Norris SL, McNally TK, Zhang X, Burda B, Chan B, Chowdhury FM, et al.
Published norms underestimate the health-related quality of life among
persons with type 2 diabetes. J Clin Epidemiol. 2011;64:358–65.
doi:10.1016/j.jclinepi.2010.04.016.
22. Nezu S, Okamoto N, Morikawa M, Saeki K, Obayashi K, Tomioka K, et al.
Health-related quality of life (HRQOL) decreases independently of chronic
conditions and geriatric syndromes in older adults with diabetes: the
Fujiwara-kyo Study. J Epidemiol. 2014;24:259–66.
23. Ayis S, Wellwood I, Rudd AG, McKevitt C, Parkin D, Wolfe CD. Variations in
Health-Related Quality of Life (HRQoL) and survival 1 year after stroke:
five European population-based registers. BMJ Open. 2015;5:e007101.
doi:10.1136/bmjopen-2014-007101.
24. Alonso J, Ferrer M, Gandek B, Ware Jr JE, Aaronson NK, Mosconi P, et al.
Health-related quality of life associated with chronic conditions in eight
countries: results from the International Quality of Life Assessment (IQOLA)
Project. Qual Life Res. 2004;13:283–98.
25. Selim AJ, Ren XS, Fincke G, Rogers W, Lee A, Kazis L. A symptom-based
measure of the severity of chronic lung disease: results from the Veterans
Health Study. Chest. 1997;111:1607–14.
26. Ruffin RE, Wilson DH, Chittleborough CR, Southcott AM, Smith B,
Christopher DJ. Multiple respiratory symptoms predict quality of life in
chronic lung disease: a population-based study of Australian adults. Qual
Life Res. 2000;9:1031–9.
27. van Manen JG, Bindels PJ, Dekker FW, Bottema BJ, van der Zee JS, Ijzermans CJ,
et al. The influence of COPD on health-related quality of life independent of
the influence of comorbidity. J Clin Epidemiol. 2003;56:1177–84.
28. Okamoto LJ, Noonan M, DeBoisblanc BP, Kellerman DJ. Fluticasone
propionate improves quality of life in patients with asthma requiring
oral corticosteroids. Ann Allergy Asthma Immunol. 1996;76:455–61.
doi:10.1016/s1081-1206(10)63463-1.
29. Wallace Jr RJ, Brown BA, Griffith DE, Girard WM, Murphy DT, Onyi GO, et al.
Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare
complex lung disease. Am J Respir Crit Care Med. 1994;149:1335–41.
doi:10.1164/ajrccm.149.5.8173775.
Asakura et al. Respiratory Research  (2015) 16:145 Page 8 of 9
30. Hasegawa N, Nishimura T, Ohtani S, Takeshita K, Fukunaga K, Tasaka S, et al.
Therapeutic effects of various initial combinations of chemotherapy
including clarithromycin against Mycobacterium avium complex pulmonary
disease. Chest. 2009;136:1569–75. doi:10.1378/chest.08-2567.
31. Jeong BH, Jeon K, Park HY, Kim SY, Lee KS, Huh HJ, et al. Intermittent
antibiotic therapy for nodular bronchiectatic Mycobacterium avium
complex lung disease. Am J Respir Crit Care Med. 2015;191:96–103.
doi:10.1164/rccm.201408-1545OC.
32. McHorney CA, Ware Jr JE, Lu JF, Sherbourne CD. The MOS 36-item
Short-Form Health Survey (SF-36): III. Tests of data quality, scaling
assumptions, and reliability across diverse patient groups. Med Care. 1994;
32:40–66.
33. Morimoto K, Iwai K, Uchimura K, Okumura M, Yoshiyama T, Yoshimori K,
et al. A steady increase in nontuberculous mycobacteriosis mortality and
estimated prevalence in Japan. Ann Am Thorac Soc. 2014;11:1–8.
doi:10.1513/AnnalsATS.201303-067OC.
34. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global
risk assessment in the primary prevention of cardiovascular disease.
Circulation. 2001;103:1813–8.
35. Jayakumar A, Vittinghoff E, Segal MR, MacKenzie WR, Johnson JL, Gitta P,
et al. Serum biomarkers of treatment response within a randomized clinical
trial for pulmonary tuberculosis. Tuberculosis (Edinb). 2015;95:415–20.
doi:10.1016/j.tube.2015.04.011.
36. Shivakoti R, Yang WT, Gupte N, Berendes S, Rosa AL, Cardoso SW, et al.
Concurrent anemia and elevated C-reactive protein predicts HIV clinical
treatment failure, including tuberculosis, after antiretroviral therapy
initiation. Clin Infect Dis. 2015;61:102–10. doi:10.1093/cid/civ265.
37. Liu X, Mayes MD, Pedroza C, Draeger HT, Gonzalez EB, Harper BE, et al. Does
C-reactive protein predict the long-term progression of interstitial lung
disease and survival in patients with early systemic sclerosis? Arthritis Care
Res (Hoboken). 2013;65:1375–80. doi:10.1002/acr.21968.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Asakura et al. Respiratory Research  (2015) 16:145 Page 9 of 9
